Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD
Authors:
Open Access
- 1 June 1998
- journal article
- clinical trial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 11 (6) , 1337-1341
Abstract
We examined whether a pretreatment with formoterol, oxitropium bromide, or salmeterol might modify the dose-response curves to inhaled salbutamol in patients with stable and partially reversible chronic obstructive pulmonary disease (COPD). Sixteen outpatients with partially reversible, stable COPD received 24 microg formoterol, 50 microg salmeterol, 200 microg oxitropium bromide, or placebo on four non-consecutive days. Spirometric testing was performed immediately before inhalation of treatment and after 2 h. A dose-response curve to inhaled salbutamol was then constructed using doses of 100, 100, 200 microg and 400 microg--that is, a total cumulative dose of 800 microg. Dose increments were given at 20 min intervals with measurements being made 15 min after each dose. Formoterol, salmeterol, or oxitropium bromide elicited a significant increase in forced expiratory volume in one second (FEV1) compared with placebo (mean differences (L) = placebo 0.05; formoterol 0.34; salmeterol 0.27; oxitropium bromide 0.23). Dose-dependent increases in FEV1 were seen (mean values (L) before salbutamol and after a cumulative dose of 100, 200, 400, and 800 microg = placebo: 1.06, 1.28, 1.35, 1.39, 1.41; formoterol: 1.33, 1.37, 1.41, 1.44, 1.44; salmeterol: 1.30, 1.33, 1.36, 1.39, 1.42; oxitropium bromide: 1.27, 1.34, 1.37, 1.41, 1.40). Statistical analysis revealed no significant differences in FEV1 and forced vital capacity (FVC) responses to salbutamol after therapy with formoterol, salmeterol, or oxitropium bromide compared with placebo. This study clearly shows that a pretreatment with a conventional dose of formoterol, salmeterol, or oxitropium bromide does not preclude the possibility of inducing a further bronchodilation with salbutamol in patients suffering from partially reversible chronic obstructive pulmonary disease.Keywords
This publication has 23 references indexed in Scilit:
- Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patientsThe Lancet, 1995
- Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response studyRespiratory Medicine, 1995
- Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease.Thorax, 1993
- The effect of increasing doses of β-agonists on airflow in patients with chronic airflow limitationRespiratory Medicine, 1993
- Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma.BMJ, 1993
- Comparison of the bronchodilator activities of oxitropium bromide, fenoterol, and their combination in patients with chronic obstructive pulmonary disease and bronchial asthmaClinical Autonomic Research, 1993
- Multicenter 1-year trial on formoterol, a new long-actingβ 2-agonist, in chronic obstructive airway diseaseLung, 1990
- Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects.Thorax, 1987
- The influence of theophylline on maximal response to salbutamol in severe chronic obstructive pulmonary diseaseEuropean Journal of Clinical Pharmacology, 1982
- Comparison of the bronchodilator and cardiovascular actions of isoprenaline, Th 1165a, terbutaline and salbutamol in cats and isolated organ preparationsZeitschrift für Die Gesamte Experimentelle Medizin, 1974